| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
We evaluated the potential of miR-221 and miR222 as novel therapeutics for lung cancer. These microRNAs are shown to induce epithelial to mesenchymal transition (EMT) in normal mammary epithelial cells. Upon introduction of miR-221 or miR222, immortalized normal human bronchial epithelial cells underwent morphological changes, suggestive of EMT, in association with expression changes in EMT-associated genes. miR-221 and miR222 promoted growth in several lung cancer cell lines but suppressed in other cell lines. Cell cycle and apoptosis analyses revealed that growth suppressive effects by miR-221 and miR-221 occur through S-phase arrest and/or apoptosis. These data suggested the potential of miR-221 and miR222 as novel therapeutics for lung cancer.
|
